NeoGenomics, Inc. (NEO) News
Follow NeoGenomics, Inc. (NEO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
What's Going On With NeoGenomics Stock Tuesday?
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ: NEO ) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026. T
LIVE | Oct 06, 2026, 05:54 PM UTC
M
NeoGenomics Shares Rise on Executive Succession and Higher Guidance
NeoGenomics (NEO) saw its shares jump 3.6% in pre-market trading following the announcement of an executive succession plan and preliminary updates indicating an increase in full-year guidance.
EARNINGS | Oct 06, 2026, 02:20 PM UTC
H
NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call
NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call
LIVE | Oct 05, 2026, 08:24 PM UTC
M
NeoGenomics Reports 3Q Revenue of About $209M
NeoGenomics reported its third-quarter revenue to be approximately $209 million.
EARNINGS | Oct 05, 2026, 08:15 PM UTC
L
Neo Energy Metals Raises £1.75 Mln Via Placing Of 269,230,769 Shares At 0.65 Pence Each
Neo Energy Metals PLC LSE:NEO
EQUITY | Sep 25, 2026, 06:26 AM UTC
L
Neo Performance Materials (NEO) Signs MOU for Rare Earth Offtake From Rainbow
Neo signed a non-binding MOU with Rainbow Rare Earths for technical support and offtake from the Phalaborwa project in South Africa, targeting NdPr oxide and a mixed heavy REE carbonate. Definitive agreements are still t
NEWS | Sep 24, 2026, 06:01 AM UTC
L
NEO: NGS and workflow solutions fuel robust growth, with innovation and operational focus driving future gains
Focused on community oncology, the company leverages a broad portfolio and workflow solutions to drive growth, with NGS revenue expanding at 26% and new products like PanTracer and RaDaR ST strengthening its competitive
NEWS | Sep 15, 2026, 01:15 PM UTC
L
NEO: NGS and MRD growth, community focus, and portfolio innovation drive strong financial outlook
Management outlined a focused strategy on community oncology, leveraging a broad portfolio and tailored solutions to drive growth. NGS and MRD are key revenue drivers, with robust financial performance and margin expansi
EARNINGS | Sep 15, 2026, 12:45 PM UTC
L
Neo Energy Metals appoints Elmarié Maritz as CFO
EQUITY | Sep 10, 2026, 06:51 AM UTC
L
AnorTech receives US$1.0 million cash and shares from Sarfartoq deal
AnorTech says it has received cash and shares after the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq ree project transaction.
MNA | Sep 03, 2026, 01:07 PM UTC
L
Neo Performance Materials Receives Cash, Shrs of Greenland Mines
Neo Performance Materials Receives Cash, Shrs of Greenland Mines
EQUITY | Sep 02, 2026, 11:01 AM UTC
M
Neo completes transfer of Sarfartoq interest to Greenland Mines
Neo announced closing of the previously announced transaction, receiving cash and shares of Greenland Mines while retaining an equity stake and offtake rights in the Sarfartoq Project.
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
NeoGenomics to participate in Morgan Stanley Global Healthcare conference
NeoGenomics, Inc. (NEO) said it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference Sept. 14–16, 2026 in New York, NY.
EQUITY | Sep 01, 2026, 11:05 AM UTC
L
Greenland Mines to close Sarfartoq rare earth deal by Sept. 1, 2026
Greenland Mines says it is set to close its Sarfartoq rare earths acquisition by Sept. 1, 2026.
MNA | Aug 27, 2026, 03:37 PM UTC
L
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
EQUITY | Aug 27, 2026, 03:14 AM UTC
L
NeoGenomics gets Medicare coverage for RaDaR ST
NeoGenomics received Medicare coverage for RaDaR ST for immunotherapy treatment response monitoring.
EQUITY | Aug 26, 2026, 08:17 PM UTC
H
NEO PT Raised to $19
NEO price target raised to $19
EQUITY | Jul 29, 2026, 01:20 PM UTC
L
NEO Q2 adj. EPS $0.05 vs. est. $0.03; adj. gross margin 48%; adjusted EBITDA $14Mm vs est $12.81Mm, up 36% year over year as revenue rose 11
NEO Q2 adj. EPS $0.05 vs. est. $0.03; adj. gross margin 48%; adjusted EBITDA $14Mm vs est $12.81Mm, up 36% year over year as revenue rose 11% to $202Mm vs. $197Mm est.; FY26 outlook raised with revenue guided to $802–$80
EARNINGS | Jul 28, 2026, 08:41 PM UTC
L
NeoGenomics raises FY26 revenue view from $797M-$803M to $802M-$806M
Consensus $800.4M. Raises...
EQUITY | Jul 28, 2026, 08:25 PM UTC
L
NeoGenomics reports Q2 EPS 5c, consensus 3c
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 08:23 PM UTC
L
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NASDAQ: NEO ) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.
EARNINGS | Jul 28, 2026, 08:06 PM UTC
L
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
EQUITY | Jul 20, 2026, 09:27 PM UTC
L
NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic
NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known
EQUITY | Jul 09, 2026, 11:10 AM UTC